19 min listen
MHC class I loss in endometrial carcinoma
FromModPath Chat
ratings:
Length:
13 minutes
Released:
Mar 2, 2021
Format:
Podcast episode
Description
MHC class I loss by tumor cells decreases tumor neoantigen presentation to the immune system and therefore represents a possible mechanism of immunotherapeutic resistance in cancers that otherwise could be good candidates for checkpoint inhibition (e.g. mismatch repair (MMR)-deficient and PD-L1-positive tumors). In this episode our guest, Dr. Anne Mills discusses her recent Modern Pathology publication on loss of MHC class 1 expression in some endometrial cancers. Study by Friedman et al, MHC class I loss in endometrial carcinoma: a potential resistance mechanism to immune checkpoint inhibition. Modern Pathology, 34, 627-636, 2021. https://www.nature.com/articles/s41379-020-00682-w Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.
Released:
Mar 2, 2021
Format:
Podcast episode
Titles in the series (58)
COVID-19 pulmonary pathology in cross Atlantic pandemic epicenters: A discussion with Dr. Borczuk of New York Presbyterian Hospital- Weill Cornell Medicine on his team findings in sixty eight COVID-19 autopsies, performed early on during the pandemic, at 3 institutions in heavily hit areas (2 USA, 1 Italy). by ModPath Chat